Ceren Sezgin, Emre Uygur, Yasemin Parlak, Busra Karatay, Sabri Barutca, Ahmet Dirican, Tevfik Sinan Sozen, Guven Arslan, Coskun Harmansah, Turkay Toklu, Ugur Avcibasi, Zumrut Biber Muftuler, Omer Aras, Gul Gumuser
{"title":"基于优化放射标记方案的mCRPC患者terbier161psma治疗","authors":"Ceren Sezgin, Emre Uygur, Yasemin Parlak, Busra Karatay, Sabri Barutca, Ahmet Dirican, Tevfik Sinan Sozen, Guven Arslan, Coskun Harmansah, Turkay Toklu, Ugur Avcibasi, Zumrut Biber Muftuler, Omer Aras, Gul Gumuser","doi":"10.1007/s10967-025-10352-3","DOIUrl":null,"url":null,"abstract":"<div><p>This study presents a novel radiolabeling technique for [<sup>161</sup>Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [<sup>116</sup> Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% ± 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies.</p></div>","PeriodicalId":661,"journal":{"name":"Journal of Radioanalytical and Nuclear Chemistry","volume":"334 9","pages":"5979 - 5988"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol\",\"authors\":\"Ceren Sezgin, Emre Uygur, Yasemin Parlak, Busra Karatay, Sabri Barutca, Ahmet Dirican, Tevfik Sinan Sozen, Guven Arslan, Coskun Harmansah, Turkay Toklu, Ugur Avcibasi, Zumrut Biber Muftuler, Omer Aras, Gul Gumuser\",\"doi\":\"10.1007/s10967-025-10352-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This study presents a novel radiolabeling technique for [<sup>161</sup>Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [<sup>116</sup> Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% ± 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies.</p></div>\",\"PeriodicalId\":661,\"journal\":{\"name\":\"Journal of Radioanalytical and Nuclear Chemistry\",\"volume\":\"334 9\",\"pages\":\"5979 - 5988\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Radioanalytical and Nuclear Chemistry\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s10967-025-10352-3\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, ANALYTICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Radioanalytical and Nuclear Chemistry","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s10967-025-10352-3","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}
Terbium-161 PSMA therapy in mCRPC patient based on an optimized radiolabeling protocol
This study presents a novel radiolabeling technique for [161Tb]-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC). The research focused on assessing the radiochemical yield, in vivo stability, and pharmacokinetics of [116 Tb]-PSMA-617 in a clinical setting. Using a sodium acetate buffer and ascorbic acid, a high radiochemical yield (97.98% ± 2.01) was achieved, ensuring stability and purity. The therapy was evaluated to a 77-year-old mCRPC patient resistant to [177Lu]-PSMA-617, showing favorable biodistribution and urinary excretion. Despite initial stability, disease progression occurred, with a TP53 mutation identified via liquid biopsy. While the method holds promise for targeted radionuclide therapy, resistance mechanisms remain a challenge, necessitating further research for optimized patient selection and treatment strategies.
期刊介绍：
An international periodical publishing original papers, letters, review papers and short communications on nuclear chemistry. The subjects covered include: Nuclear chemistry, Radiochemistry, Radiation chemistry, Radiobiological chemistry, Environmental radiochemistry, Production and control of radioisotopes and labelled compounds, Nuclear power plant chemistry, Nuclear fuel chemistry, Radioanalytical chemistry, Radiation detection and measurement, Nuclear instrumentation and automation, etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
